Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr James Davies from our MRC Molecular Haematology Unit writes in The Conversation about genome editing, its power for good... and the ethical issues that we are already facing.

We are entering a new era as a species. For the first time, we are not only able to read our genetic code but also edit it. This will revolutionise our ability to treat disease and it will improve the lives of millions if not billions of people. But it means that, if we want to, we can now edit human embryos to “improve” the characteristics of our children. We will be able to create designer babies and these changes will be passed on to their descendants, which will change the human species forever.

It is worth thinking about the scale of what we can now do. The human genome is made up of 3 billion characters, which is about ten times the size of Encyclopaedia Britannica. This contains all the information needed to make a human, and it determines nearly all our characteristics as individuals (not only height, athletic performance and IQ but also our personality and even political views). We completed the first sequence of the human genome around 20 years ago at a cost of US$2.7 billion. We can now sequence a genome for less than the cost of an MRI scan.

Read the full piece here.

Similar stories

Anjali Kusumbe receives the RMS Life Sciences Medal

The Royal Microscopical Society awards celebrate the best in microscopy, recognising those making a special contribution to microscopy, cytometry and imaging.

Wellcome Trust funding success for Jim Hughes and James Davies

£3.6 million in funding awarded by the Wellcome Trust to combine cutting-edge 3D genome technologies with machine learning approaches to decipher the role of the non-coding genome in disease.

Study of T-cell receptor activation leads to surprising discovery

A study from Davis Group is the first to describe the structure of the T-cell receptor when bound to an activating ligand. The findings shed light on an important trigger in the immune system, and suggest a completely new process by which cell receptors can be activated.

Biotech spinout MiroBio acquired by Gilead Sciences for ~£332m

Co-founded by Prof. Simon Davis, MiroBio focuses on developing therapeutics for inflammatory diseases.

Seven research groups secure LEAF Sustainability Awards

The Laboratory Efficiency Assessment Framework (LEAF) aims to support research groups to embed sustainability into their work.